Patient-Centered Economic Burden of Exudative Age-Related Macular Degeneration: Retrospective Cohort Study

• Published in: JMIR public health and surveillance Vol. 9; p. e49852
• Main Authors: Choi, Kyungseon, Park, Sang Jun, Han, Sola, Mun, Yongseok, Lee, Da Yun, Chang, Dong-Jin, Kim, Seok, Yoo, Sooyoung, Woo, Se Joon, Park, Kyu Hyung, Suh, Hae Sun
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 08.12.2023
• Subjects: Cohort analysis; Costs; Data models; Diabetes; Disease; Drugs; Economic impact; Economic policy; Edema; Financial Stress; Generalized linear models; Health care expenditures; Hospitals; Humans; Informatics; Macular degeneration; Macular Degeneration - diagnosis; Macular Degeneration - epidemiology; Middle Aged; National health insurance; Patient-Centered Care; Patients; Reimbursement; Retrospective Studies; Vascular endothelial growth factor; Verteporfin; United States > US; South Korea; common data model; retrospective cohort study; cost of illness; blindness; age-related macular degeneration; economic burden
• ISSN: 2369-2960; 2369-2960
• DOI: 10.2196/49852

Exudative age-related macular degeneration (AMD), one of the leading causes of blindness, requires expensive drugs such as anti-vascular endothelial growth factor (VEGF) agents. The long-term regular use of effective but expensive drugs causes an economic burden for patients with exudative AMD. However, there are no studies on the long-term patient-centered economic burden of exudative AMD after reimbursement of anti-VEGFs. This study aimed to evaluate the patient-centered economic burden of exudative AMD for 2 years, including nonreimbursement and out-of-pocket costs, compared with nonexudative AMD using the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). This retrospective cohort study was conducted using the OMOP CDM, which included 2,006,478 patients who visited Seoul National University Bundang Hospital from June 2003 to July 2019. We defined the exudative AMD group as patients aged >50 years with a diagnosis of exudative AMD and a prescription for anti-VEGFs or verteporfin. The control group was defined as patients aged >50 years without a diagnosis of exudative AMD or a prescription for anti-VEGFs or verteporfin. To adjust for selection bias, controls were matched by propensity scores using regularized logistic regression with a Laplace prior. We measured any medical cost occurring in the hospital as the economic burden of exudative AMD during a 2-year follow-up period using 4 categories: total medical cost, reimbursement cost, nonreimbursement cost, and out-of-pocket cost. To estimate the average cost by adjusting the confounding variable and overcoming the positive skewness of costs, we used an exponential conditional model with a generalized linear model. We identified 931 patients with exudative AMD and matched 783 (84.1%) with 2918 patients with nonexudative AMD. In the exponential conditional model, the total medical, reimbursement, nonreimbursement, and out-of-pocket incremental costs were estimated at US $3426, US $3130, US $366, and US $561, respectively, in the first year and US $1829, US $1461, US $373, and US $507, respectively, in the second year. All incremental costs in the exudative AMD group were 1.89 to 4.25 and 3.50 to 5.09 times higher in the first and second year, respectively, than those in the control group (P<.001 in all cases). Exudative AMD had a significantly greater economic impact (P<.001) for 2 years on reimbursement, nonreimbursement, and out-of-pocket costs than nonexudative AMD after adjusting for baseline demographic and clinical characteristics using the OMOP CDM. Although economic policies could relieve the economic burden of patients with exudative AMD over time, the out-of-pocket cost of exudative AMD was still higher than that of nonexudative AMD for 2 years. Our findings support the need for expanding reimbursement strategies for patients with exudative AMD given the significant economic burden faced by patients with incurable and fatal diseases both in South Korea and worldwide.